Cardiotoxicity Associated with Antineoplastic Therapy: A Multidisciplinary Approach to Personalized Monitoring Using Radionuclide Imaging and Molecular Biomarkers.

Authors

Lidia Anca Kajanto, Dana Lucia Stănculeanu, Anita-Cristina Ionescu, Ioan Sã Rbu, Ion Alexandru Popovici, Ionuţ Bulbuc, Mihaela Pundiche, Ileana-Delia Manea-Sabău, Andreea Diana Kajanto, Bogdan Caraban

Published in

Chirurgia (Bucharest, Romania : 1990). Volume 121. Issue 3. Pages 328-336.

Abstract

Background: Cardiotoxicity associated with antineoplastic therapy may compromise both cardiovascular outcomes and continuity of cancer treatment. We evaluated a multimodal strategy based on radionuclide imaging and molecular biomarkers for early detection of subclinical cardiac dysfunction and for personalized monitoring applicable in multidisciplinary oncologic care. Methodology: In this prospective, observational, single-center study, 90 adults with breast cancer, lymphoma, or lung cancer receiving potentially cardiotoxic regimens were evaluated at baseline (T0), after 3-4 cycles (T1), at treatment completion (T2), and at 6-month follow-up (T3). Antineoplastic exposure was classified according to dominant cardiotoxic profile, including anthracycline-containing regimens, anti-HER2 therapy, platinum/taxane-based chemotherapy, immunotherapy, and targeted agents when used. Monitoring included clinical assessment, ECG, MUGA/gated SPECT, echocardiography with LVEF and GLS, and serial hs-Tn, NT-proBNP, and sST2. Results: Median age was 56 years, and 62% of patients were women. Mean baseline LVEF was 60Ã+-5% and mean GLS â? '19.5Ã+-2.1%. During treatment, hs-Tn, NT-proBNP, and sST2 increased progressively, while LVEF declined to 57Ã+-6% and GLS to â? '16.6Ã+-2.5% at treatment completion. Imaging-defined cardiac dysfunction occurred in 30% of patients, including overt cardiotoxicity in 10%. Changes in hs-Tn correlated most strongly with GLS (r=â? '0.42, p=0.002). The integrated model showed the best predictive performance (AUC 0.91). Conclusions: Beyond diagnostic value, this multimodal model may support multidisciplinary decision-making in surgical oncology by identifying patients who require intensified surveillance, early cardioprotection, preoperative optimization, or adjustment of treatment sequencing. The findings should be interpreted as clinically promising and hypothesis-generating, requiring multicenter validation before routine implementation.

PMID:
42478986
Bibliographic data and abstract were imported from PubMed on 21 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.